BioStem Technologies today announced that it has appointed three key members to its scientific advisory board (SAB). The board, chaired by Kenneth Warrington, Ph.D., welcomes new members Jeffrey Harrison, Ph.D., Daniel Shelly, Ph.D., and Shaun Opie, Ph.D.
BioStem announced that it has received the TRIP (TRG Rapid Inquiry Program) response from the FDA’s Tissue Reference Group (TRG) for the Company’s amniotic membrane allograft, VENDAJE™
BioStem Technologies, Inc. announced it engaged D. Brooks and Associates CPA's, P.A. as the Company’s PCAOB registered certified public accounting firm for the 2020 and 2019 fiscal years.
BioStem Technologies today announced, in partnership with Veterans Medical Distributors Inc., a Service-Disabled Veteran-Owned Small Business (SDVOSB), that it has been awarded a five-year Federal Supply Schedule (FSS) contract for its VENDAJE™ line of amnion membrane allografts, by the U.S. Department of Veterans Affairs (VA).
BioStem Life Sciences has signed a Master Service Agreement with a new customer to manufacture the customer’s amniotic membrane platform for the next two years
